Illumina Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
9,300
- Stock Symbol
-
ILMN
- Investments
-
80
- Share Price
-
$103.57
- (As of Wednesday Closing)
Illumina General Information
Description
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Contact Information
Website
www.illumina.comCorporate Office
- 5200 Illumina Way
- San Diego, CA 92122
- United States
Corporate Office
- 5200 Illumina Way
- San Diego, CA 92122
- United States
Illumina Timeline
Illumina Stock Performance
As of 12-Feb-2025, Illumina’s stock price is $103.57. Its current market cap is $16.4B with 159M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $103.57 | $100.68 | $97.28 - $156.66 | $16.4B | 159M | 2.28M | -$7.69 |
Illumina Financials Summary
As of 31-Dec-2024, Illumina has a trailing 12-month revenue of $4.37B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 22,928,718 | 22,928,718 | 23,450,312 | 33,331,060 |
| Revenue | 4,372,000 | 4,372,000 | 4,504,000 | 4,584,000 |
| EBITDA | (1,052,000) | (1,052,000) | (666,000) | (3,927,000) |
| Net Income | (1,223,000) | (1,223,000) | (1,161,000) | (4,404,000) |
| Total Assets | 6,303,000 | 6,303,000 | 10,111,000 | 12,252,000 |
| Total Debt | 2,543,000 | 2,543,000 | 2,262,000 | 3,555,000 |
Illumina Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Illumina Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Illumina Comparisons
Industry
Financing
Details
Illumina Competitors (42)
One of Illumina’s 42 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Bio-Techne | Corporation | Minneapolis, MN | ||||
| Pacific Biosciences | Formerly VC-backed | Menlo Park, CA | ||||
| QuidelOrtho | Corporation | San Diego, CA | ||||
| Idexx Laboratories | Formerly VC-backed | Westbrook, ME |
Illumina Patents
Illumina Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240209438-A1 | Tuning and calibration features of a sequence-detection system | Pending | 11-Mar-2024 | ||
| US-20250046399-A1 | Compression techniques for genomic data | Pending | 03-Aug-2023 | ||
| US-20250010263-A1 | Selective reactions in microreactor arrays | Pending | 06-Jul-2023 | ||
| US-20250010285-A1 | Flow cells with dendron architecture | Pending | 30-Jun-2023 | ||
| US-20250002985-A1 | Using apertures to capture polynucleotides on particles | Pending | 30-Jun-2023 | C12Q1/6844 |
Illumina Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Illumina Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Illumina Investments & Acquisitions (80)
Illumina’s most recent deal was a Later Stage VC with Truveta for . The deal was made on 09-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Truveta | 09-Jan-2025 | Later Stage VC | Enterprise Systems (Healthcare) | ||
| Fluent BioSciences | 09-Jul-2024 | Merger/Acquisition | Biotechnology | ||
| Partek | 01-Jan-2024 | Merger/Acquisition | Biotechnology | ||
| Concr | 05-Oct-2022 | Seed Round | Therapeutic Devices | ||
| FOM Technologies (flagship coating system) | 20-Sep-2022 | Corporate Asset Purchase | Buildings and Property |
Illumina ESG
Risk Overview
Risk Rating
Updated December, 11, 2024
18.37 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Biotechnology
Subindustry
of 368
Rank
Percentile
Illumina Exits (20)
Illumina’s most recent exit was on 16-Mar-2022 from 4SR Biosciences. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 4SR Biosciences | 16-Mar-2022 | Completed |
|
||
| Neurolytic Healthcare | 29-Dec-2021 | Completed |
|
||
| SomaLogic Operating Company | 31-Aug-2021 | Completed |
|
||
| Ginkgo Bioworks | 15-May-2020 | Completed |
|
||
| Astarte Medical | 17-Oct-2018 | Accelerator/Incubator | Completed |
Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Illumina Ventures | Foster City, CA | 2016 | |
| Emedgene | Tel Aviv, Israel | 2015 | |
| GRAIL | Menlo Park, CA | 2015 | |
| Illumina Accelerator | Foster City, CA | 2014 | |
| Partek | Chesterfield, MO | 1993 |
Illumina FAQs
-
When was Illumina founded?
Illumina was founded in 1998.
-
Where is Illumina headquartered?
Illumina is headquartered in San Diego, CA.
-
What is the size of Illumina?
Illumina has 9,300 total employees.
-
What industry is Illumina in?
Illumina’s primary industry is Diagnostic Equipment.
-
Is Illumina a private or public company?
Illumina is a Public company.
-
What is Illumina’s stock symbol?
The ticker symbol for Illumina is ILMN.
-
What is the current stock price of Illumina?
As of 12-Feb-2025 the stock price of Illumina is $103.57.
-
What is the current market cap of Illumina?
The current market capitalization of Illumina is $16.4B.
-
What is Illumina’s current revenue?
The trailing twelve month revenue for Illumina is $4.37B.
-
Who are Illumina’s competitors?
Bio-Rad Laboratories, Bio-Techne, Pacific Biosciences, QuidelOrtho, and Idexx Laboratories are some of the 42 competitors of Illumina.
-
What is Illumina’s annual earnings per share (EPS)?
Illumina’s EPS for 12 months was -$7.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
